Markers for diagnosis of pulmonary inflammation and methods related thereto
AssigneeNational Jewish Health
InventorsMilene Saavedra, Jerry Nick
Life of this patent
Estimating the term…
Abstract
The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.
Claims8
-11. (canceled)
A method to treat acute pulmonary exacerbation in a subject having cystic fibrosis and having had a first administration of at least one antibiotic comprising further administering at least one antibiotic to the subject if the subject had different mRNA expression levels of CD64, PLXND1, HCA112, TLR2, CD163 and IL32 genes compared to the mRNA expression levels of the same genes from the subject before the first administration of the at least one antibiotic.
Dependencies are inferred from the claim text.